Company intelligence / Profile preview
Laevoroc Oncology
Hünenberg, Zug, Switzerlandlaevoroc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Laevoroc Oncology is a Swiss oncology biotech developing next-generation immunotherapies and chemotherapeutics targeting high unmet needs in hematological malignancies, brain tumors, and solid tumors. Its lead program LR09 received FDA Orphan Drug Designation for relapsed leukemia after allogeneic stem cell transplant. The company’s pipeline includes an oral gemcitabine prodrug for solid tumors and a CNS ATR inhibitor for brain cancer. Most programs are at the preclinical stage or preparing to enter clinical trials.
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecules (e.g., oral gemcitabine prodrug, PNP inhibitor Ulodesine/LR09)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Joint venture with Lipomed AG on oral gemcitabine projectResearch collaborations with UCLA & Fred Hutchinson Cancer Center on LR09 development
Beyond the preview
Go deeper on Laevoroc Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laevoroc Oncology.